The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

proacta.com

Total Raised

$49.08M

Investors Count

11

Deal Terms

2

Proacta Funding, Proacta Valuation & Proacta Revenue

5 Fundings

Proacta's latest funding round was a Convertible Note for $0.5M on December 23, 2011.

Proacta's valuation in February 2007 was $102.39M.

Proacta's latest post-money valuation is from February 2007.

Sign up for a free trial to see Proacta's valuations in January 2006 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

12/23/2011

Convertible Note

$0.5M

0

FY undefined

1

2/8/2010

Debt

$99M

0

FY undefined

0

2/25/2009

Grant

$99M

0

FY undefined

0

2/23/2007

Series B

$99M

$102.39M

0

FY undefined

10

1/16/2006

Series A

$99M

$99M

0

FY undefined

0

Date

12/23/2011

2/8/2010

2/25/2009

2/23/2007

1/16/2006

Round

Convertible Note

Debt

Grant

Series B

Series A

Amount

$0.5M

$99M

$99M

$99M

$99M

Investors

Valuation

$102.39M

$99M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

0

0

10

0

Proacta Deal Terms

2 Deal Terms

Proacta's deal structure is available for 2 funding rounds, including their Series B from February 23, 2007.

Round

Series B

Series A

Funding Date

$99M

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

$99M

Liquidation Preferences

$99M

Liquidation Price

Participation

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

Board Voting

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series B

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Proacta Investors

11 Investors

Proacta has 11 investors. Alta Partners invested in Proacta's Series A funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

1/16/2006

12/23/2011

4
Debt, Convertible Note (2011), Series B (2007), Series A (2006)

Venture Capital

California

1/16/2006

12/23/2011

4
Debt, Convertible Note (2011), Series B (2007), Series A (2006)

Venture Capital

Australia

2/23/2007

12/23/2011

3
Debt, Convertible Note (2011), Series B (2007)

Venture Capital

Massachusetts

00/00/0000

00/00/0000

No 8 Ventures

Subscribe to see more

Venture Capital

New Zealand

00/00/0000

00/00/0000

Genentech

Subscribe to see more

Corporation

California

First funding

1/16/2006

1/16/2006

2/23/2007

00/00/0000

00/00/0000

Last Funding

12/23/2011

12/23/2011

12/23/2011

00/00/0000

00/00/0000

Investor

No 8 Ventures

Genentech

Rounds

4
Debt, Convertible Note (2011), Series B (2007), Series A (2006)
4
Debt, Convertible Note (2011), Series B (2007), Series A (2006)
3
Debt, Convertible Note (2011), Series B (2007)

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Corporation

Location

California

Australia

Massachusetts

New Zealand

California

You May Also Like

A
Agenta Biotechnologies

Agenta's technologies capitalize on variations of the important biomolecules called proteoglycans, a class of molecules that can promote healing through a variety of known mechanisms. As therapeutics, they can be applied to bone and skin, or serve as coatings for various devices. It is Agenta's mission to be the world provider in manipulating proteoglycans for therapeutic use.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

P
Pro-Cure Therapeutics

Prostate Cancer - Pro-Cure Therapeutics - Enabling the development of a cure for prostate cancer based on stem cells

C
CellSignals

CellSignals applies its technology in chiral synthesis to develop lipid mediators pertinent to intracellular signal transduction and cancer biology. Currently CellSignals' product line has grown to more than 40 chemicals covering a variety of inositol polyphosphates and phosphatidylinositol polyphosphates. CellSignals is actively developing small-molecules, orally bio-available therapeutics for the treatments of breast, skin cancers, and leukemia.

T
TenX Biopharma

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.

F
Femta Pharmaceuticals

Femta is developing a new generation of antibody therapeutics for major disease indications.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.